CY1105745T1 - Χρηση της 11βητα-(4-ακετυλφαινυλ)-17βητα-υδροξυ-17αλφα(1,1,2,2-πενταφθοροαιθυλ)οιστρα-4,9-διεν-3-ονη για την παρασκευη ενος φαρμακου για την θεραπεια του καρκινου του μαστου, των ωοθηκων και του ενδομητριου, του μυελωματος και του μηνιγγιωματος - Google Patents
Χρηση της 11βητα-(4-ακετυλφαινυλ)-17βητα-υδροξυ-17αλφα(1,1,2,2-πενταφθοροαιθυλ)οιστρα-4,9-διεν-3-ονη για την παρασκευη ενος φαρμακου για την θεραπεια του καρκινου του μαστου, των ωοθηκων και του ενδομητριου, του μυελωματος και του μηνιγγιωματοςInfo
- Publication number
- CY1105745T1 CY1105745T1 CY20061101564T CY061101564T CY1105745T1 CY 1105745 T1 CY1105745 T1 CY 1105745T1 CY 20061101564 T CY20061101564 T CY 20061101564T CY 061101564 T CY061101564 T CY 061101564T CY 1105745 T1 CY1105745 T1 CY 1105745T1
- Authority
- CY
- Cyprus
- Prior art keywords
- acetylphenyl
- dien
- pentafluoroethyl
- hydroxy
- treatment
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 210000004696 endometrium Anatomy 0.000 title 1
- 206010027191 meningioma Diseases 0.000 title 1
- 201000000050 myeloid neoplasm Diseases 0.000 title 1
- 230000003623 progesteronic effect Effects 0.000 abstract 4
- 239000003418 antiprogestin Substances 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000018199 S phase Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000022131 cell cycle Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24099100P | 2000-10-18 | 2000-10-18 | |
| EP00250342 | 2000-10-18 | ||
| PCT/EP2001/012006 WO2002032432A1 (en) | 2000-10-18 | 2001-10-17 | Use of antiprogestins for the induction of apoptosis in a cell |
| EP01987669A EP1326617B9 (en) | 2000-10-18 | 2001-10-17 | Use of 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2-pentafluoroethyl)estra-4,9-dien-3-one for the preparation of a medicament for the treatment fo breast, ovarian, endometrial cancer, myeloma and meningioma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1105745T1 true CY1105745T1 (el) | 2010-12-22 |
Family
ID=26072952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061101564T CY1105745T1 (el) | 2000-10-18 | 2006-11-01 | Χρηση της 11βητα-(4-ακετυλφαινυλ)-17βητα-υδροξυ-17αλφα(1,1,2,2-πενταφθοροαιθυλ)οιστρα-4,9-διεν-3-ονη για την παρασκευη ενος φαρμακου για την θεραπεια του καρκινου του μαστου, των ωοθηκων και του ενδομητριου, του μυελωματος και του μηνιγγιωματος |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1326617B9 (enExample) |
| JP (1) | JP2004511523A (enExample) |
| KR (1) | KR100668024B1 (enExample) |
| CN (1) | CN1209111C (enExample) |
| AT (1) | ATE334683T1 (enExample) |
| AU (2) | AU2361902A (enExample) |
| BG (1) | BG107744A (enExample) |
| BR (1) | BR0114696A (enExample) |
| CA (1) | CA2423020C (enExample) |
| CY (1) | CY1105745T1 (enExample) |
| CZ (1) | CZ299823B6 (enExample) |
| DE (1) | DE60121980T2 (enExample) |
| DK (1) | DK1326617T3 (enExample) |
| EA (1) | EA010593B1 (enExample) |
| EE (1) | EE200300157A (enExample) |
| ES (1) | ES2269492T3 (enExample) |
| HR (1) | HRP20030388A2 (enExample) |
| HU (1) | HUP0301433A3 (enExample) |
| IL (2) | IL154976A0 (enExample) |
| MX (1) | MXPA03002955A (enExample) |
| NO (1) | NO20031741L (enExample) |
| NZ (1) | NZ538347A (enExample) |
| PL (1) | PL360157A1 (enExample) |
| PT (1) | PT1326617E (enExample) |
| SI (1) | SI1326617T1 (enExample) |
| SK (1) | SK4702003A3 (enExample) |
| UA (1) | UA76729C2 (enExample) |
| WO (1) | WO2002032432A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY27301A1 (es) * | 2001-05-25 | 2003-02-28 | Schering Ag | Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata |
| US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| CA2683517A1 (en) * | 2007-04-23 | 2008-10-30 | Bayer Schering Pharma Aktiengesellschaft | Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases |
| US20080268041A1 (en) * | 2007-04-23 | 2008-10-30 | Jens Hoffmann | Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases |
| CA2683809A1 (en) * | 2007-04-23 | 2008-10-30 | Bayer Schering Pharma Aktiengesellschaft | Progesterone-receptor antagonist for use in brca alone or as combination with antiestrogen |
| GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| AU2012318618B2 (en) * | 2011-10-04 | 2017-01-12 | Invivis Pharmaceuticals Inc. | Methods and systems for identifying and treating anti-progestin sensitive tumors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19706061A1 (de) * | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
-
2001
- 2001-10-17 SK SK470-2003A patent/SK4702003A3/sk not_active Application Discontinuation
- 2001-10-17 DE DE60121980T patent/DE60121980T2/de not_active Expired - Fee Related
- 2001-10-17 AT AT01987669T patent/ATE334683T1/de not_active IP Right Cessation
- 2001-10-17 NZ NZ538347A patent/NZ538347A/en unknown
- 2001-10-17 KR KR1020037005360A patent/KR100668024B1/ko not_active Expired - Fee Related
- 2001-10-17 EP EP01987669A patent/EP1326617B9/en not_active Expired - Lifetime
- 2001-10-17 PT PT01987669T patent/PT1326617E/pt unknown
- 2001-10-17 EA EA200300479A patent/EA010593B1/ru not_active IP Right Cessation
- 2001-10-17 EE EEP200300157A patent/EE200300157A/xx unknown
- 2001-10-17 AU AU2361902A patent/AU2361902A/xx active Pending
- 2001-10-17 MX MXPA03002955A patent/MXPA03002955A/es active IP Right Grant
- 2001-10-17 CA CA002423020A patent/CA2423020C/en not_active Expired - Fee Related
- 2001-10-17 JP JP2002535670A patent/JP2004511523A/ja active Pending
- 2001-10-17 ES ES01987669T patent/ES2269492T3/es not_active Expired - Lifetime
- 2001-10-17 WO PCT/EP2001/012006 patent/WO2002032432A1/en not_active Ceased
- 2001-10-17 HR HR20030388A patent/HRP20030388A2/hr not_active Application Discontinuation
- 2001-10-17 UA UA2003054311A patent/UA76729C2/uk unknown
- 2001-10-17 CN CNB018175694A patent/CN1209111C/zh not_active Expired - Fee Related
- 2001-10-17 AU AU2002223619A patent/AU2002223619B2/en not_active Ceased
- 2001-10-17 BR BR0114696-3A patent/BR0114696A/pt not_active Application Discontinuation
- 2001-10-17 HU HU0301433A patent/HUP0301433A3/hu unknown
- 2001-10-17 SI SI200130648T patent/SI1326617T1/sl unknown
- 2001-10-17 PL PL01360157A patent/PL360157A1/xx not_active Application Discontinuation
- 2001-10-17 CZ CZ20031073A patent/CZ299823B6/cs not_active IP Right Cessation
- 2001-10-17 IL IL15497601A patent/IL154976A0/xx active IP Right Grant
- 2001-10-17 DK DK01987669T patent/DK1326617T3/da active
-
2003
- 2003-03-18 IL IL154976A patent/IL154976A/en not_active IP Right Cessation
- 2003-04-15 NO NO20031741A patent/NO20031741L/no not_active Application Discontinuation
- 2003-04-18 BG BG107744A patent/BG107744A/bg unknown
-
2006
- 2006-11-01 CY CY20061101564T patent/CY1105745T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1104981T1 (el) | Χρηση των αντιπρογεστερονων για προληψη και αντιμετωπιση των εξαρτωμενων απο ορμονες ασθενειων | |
| RU2004121162A (ru) | Применение анастрозола для лечения женщин в постклимактерическом периоде, которые страдают ранним раком молочной железы | |
| EE200300157A (et) | Antiprogestiinide kasutamine apoptoosi esilekutsumiseks rakus | |
| ES2348038T5 (es) | Preparado polifásico para la contracepción sobre la base de un estrógeno natural | |
| ECSP034606A (es) | Uso de antiprogestinas para la induccion de apoptosis en una celula | |
| EA200200943A1 (ru) | Гормональная терапия рака молочной железы | |
| EA200501739A1 (ru) | Композиция, содержащая антагонисты рецептора прогестерона и чистые антиэстрогены, предназначенные для профилактики и лечения гормонзависимых заболеваний | |
| JP2004511523A5 (enExample) | ||
| BRPI0414945A (pt) | regimes contraceptivos trifásicos estendidos | |
| DE60202954D1 (de) | Tetrahydrochinolin-derivate zur behandlung von krankheiten ausgelöst durch zu hohem oder zu niedrigem oestrogenspiegel | |
| EA200300480A1 (ru) | Применение антипрогестинов для профилактики и лечения гормонозависимых заболеваний | |
| UY29861A1 (es) | Uso de valerato de estradiol en combinación con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepcion oral | |
| TW200733955A (en) | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases | |
| CY1112775T1 (el) | Χρηση βαλεριανικης οιστραδιολης σε συνδυασμο με dienogest για την απο του στοματος θεραπεια της δυσλειτουργικης αιμορραγιας της μητρας σε ενοτητα με αντισυλληψη απο του στοματος | |
| Pannuti et al. | Surgical adjuvant hormonal therapy with high dose medroxyprogesterone acetate (MAP) in breast cancer. Results 36 months after mastectomy | |
| BR0010070A (pt) | Uso de org 33245, kit contraceptivo, meio combinado para a dosagem de um progestogênio e um antiprogestogênio, e, métodos de contracepção, e de tratamento de sangramento uterino irregular ou de ruptura em uma fêmea utilizando uma preparação somente de progestogênio |